Preventive measurement for vaccine brak of Marek's Disease, Divelopment of the vaccine in particular

马立克氏病疫苗的预防措施，特别是疫苗的开发

基本信息

批准号：
60860031
负责人：
MIKAMI Takeshi
金额：
$ 16.13万
依托单位：
Faculty of Veterinary Medicine, Hokkaido University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Developmental Scientific Research
财政年份：
1985
资助国家：
日本
起止时间：
1985 至 1987
项目状态：
已结题

项目摘要

The final aim of the present study is to develop Marek's disease (MD) vaccine which prevents the vaccine break induced by MD. The following results were obtained at Present.1) The group of MD virus (MDV) and herpesvirus of turkey (HVT) is serologically devided into 3 groups. Many hybridoma secreting monoclonal antibody specific to each group or strain used as inoculum were developed. By using these antibodies, it became possible to identify the serotype of the viruses isolated from th field. Further, several monoclonal antibodies specific to MD lymphoma cells were developed for identification of MD tumor cells.2) The incidence of MD and effect of HVT vaccine in Japanese quails were investigated. Pathological lesions specific to MD were observed in many quails. There was a positive correlation between the incidence of lymphomatous changes and the prosence of MMV-specific antigen in feather follicle, and there was a negative correlation between the incidence of lympomatous changes and the presence of antibody against HVT on a flock basis. the MDV isolated from the quails belongs to serotype 1 and these were highly pathogenic to chickens. the similar virus was also isolated from chikens in field.3) It is essential to isolate the new type of non-oncogenic MDV for development of the MD vaccine to control the vaccine break of MD. Attempts were made to isolate the virus from 13 chickens and 10 pheasant. Thirteen viruses isolated from cell of th chickens, and all of the viruses belong to serotype 2 as identified by the monoclonal antibody.By using these viruses, it is feasible to develop the more effective vaccine fought against vaccine break of MD in the near future.

本研究的最终目的是开发马立克氏病（MD）疫苗，以防止马立克氏病引起的疫苗失效。目前获得以下结果： 1)MD病毒(MDV)和火鸡疱疹病毒(HVT)在血清学上分为3组。开发了许多分泌对用作接种物的各组或菌株具有特异性的单克隆抗体的杂交瘤。通过使用这些抗体，可以鉴定从现场分离的病毒的血清型。此外，还开发了几种针对MD淋巴瘤细胞的单克隆抗体，用于鉴定MD肿瘤细胞。2)研究了日本鹌鹑MD的发生率和HVT疫苗的效果。在许多鹌鹑中观察到MD特有的病理损伤。在鸡群中，淋巴瘤的发生率与羽毛囊中MMV特异性抗原的存在呈正相关，而淋巴瘤的发生率与HVT抗体的存在呈负相关。从鹌鹑中分离出的MDV属于血清1型，对鸡具有高致病性。田间从鸡中也分离到了类似的病毒。3)分离新型非致癌性MDV对于MD疫苗的研制、控制MD的破毒至关重要。尝试从 13 只鸡和 10 只野鸡中分离出病毒。从鸡细胞中分离出13种病毒，经单克隆抗体鉴定，这些病毒均属于血清2型。利用这些病毒，在不久的将来开发出更有效的抗MD疫苗是可行的。